Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
Billionaire Philippe Laffont Just Dumped CoreWeave and Opened a Position in a Stock That Soared Nearly 50% in January.
05:10am, Saturday, 21'st Feb 2026
Philippe Laffont bought shares of CoreWeave in the first quarter of last year and recently closed that position. The investor favors tech stocks and innovators.
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Cuts Stake in Moderna, Inc. $MRNA
04:08am, Saturday, 21'st Feb 2026
BNP PARIBAS ASSET MANAGEMENT Holding S.A. cut its holdings in shares of Moderna, Inc. (NASDAQ: MRNA) by 70.5% during the third quarter, according to the company in its most recent filing with the Secu
Market Today: Blue Owl payout, GDP miss, oil and EV moves
05:36pm, Friday, 20'th Feb 2026
Guru Stock PicksGeorge Soros has made the following transactions:Reduce in SPSB by 5.19%Sold out in MMYTAdd in AAMI by 61.3%New position in COINStock News Blue
First Look: Amazon tops Walmart; WBD--Netflix saga; oil up
07:38am, Friday, 20'th Feb 2026
Stock News Oil climbs on Iran risk: Crude headed for its first weekly gain in three weeks as tensions rose over potential U.S. strikes on Iran and possible Stra
Market Today: Amazon Overtakes Walmart; Blue Owl Rattles Credit; FDA Eyes Moderna Flu Shot
05:36pm, Thursday, 19'th Feb 2026
Guru Stock PicksLi Lu has made the following transactions:Sold out in SOCNew position in CROXStock News Stocks slip, private credit hit, oil climbs: Blue Owl Ca
BioNTech sues Moderna for patent infringement over COVID-19 shots
01:25pm, Thursday, 19'th Feb 2026
Biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging that Moderna's COVID-19 vaccine mNexspike infringes a patent related to BioNTech and Pfizer's competing
Moderna Stock Jumps After FDA Reverses Course on Flu Shot
11:30am, Thursday, 19'th Feb 2026
MRNA stock rises 6% as the FDA agrees to review its flu vaccine filing after a surprise reversal, with a decision expected by Aug. 5, 2026.
First Look: Walmart beat, Meta trial, FDA eyes Moderna
07:39am, Thursday, 19'th Feb 2026
Stock News Zuckerberg testifies in youth harm case: Meta Platforms (META) CEO Mark Zuckerberg defended Instagram's design and policies in a Los Angeles trial ov
Moderna to Present at Upcoming Conferences in March 2026
07:00am, Thursday, 19'th Feb 2026
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 19, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 46th Annual Hea
Thrivent Financial for Lutherans Has $345,000 Stake in Moderna, Inc. $MRNA
04:52am, Thursday, 19'th Feb 2026
Thrivent Financial for Lutherans reduced its position in shares of Moderna, Inc. (NASDAQ: MRNA) by 85.7% in the undefined quarter, according to the company in its most recent 13F filing with the Secur
Moderna (NASDAQ:MRNA) Shares Gap Up Following Analyst Upgrade
01:59am, Thursday, 19'th Feb 2026
Moderna, Inc. (NASDAQ: MRNA - Get Free Report) gapped up before the market opened on Wednesday after The Goldman Sachs Group raised their price target on the stock from $36.00 to $41.00. The stock had
3 Once-in-a-Decade Buying Opportunities
06:10pm, Wednesday, 18'th Feb 2026
These three stocks have slipped, but their long-term prospects remain bright. These companies are leaders in their fields.
Market Today: Moderna rebounds; oil and gold jump
05:34pm, Wednesday, 18'th Feb 2026
Guru Stock PicksLouis Moore Bacon has made the following transactions:Reduce in XLF by 69.62%Sold out in CEGAdd in CLS by 386.7%New position in CLJoel Greenblat
Wednesday's Final Takeaways: MRNA Flu Vaccine & Oil Creeps Higher
05:00pm, Wednesday, 18'th Feb 2026
Marley Kayden and Sam Vadas turn headlines in Big Tech and beyond for their final takeaways. Among the unsung stories: crude oil's climb on geopolitical tensions and the FDA readying to review Moderna
FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars
01:20pm, Wednesday, 18'th Feb 2026
The stock's movement comes after the U.S. Food and Drug Administration (FDA) notified Moderna that its biologics license application for mRNA-1010 will proceed to review, adding pressure as broader ma
